<http://www.wikidata.org/entity/statement/Q33264821-71AF6BA5-CC18-49AD-99A6-4833EB686B10>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://www.wikidata.org/reference/ad859fa60d174618396704813fee87f46b591d2a> .
<http://www.wikidata.org/entity/statement/Q33264821-71AF6BA5-CC18-49AD-99A6-4833EB686B10>	<http://wikiba.se/ontology#rank>	<http://wikiba.se/ontology#NormalRank> .
<http://www.wikidata.org/entity/statement/Q33264821-71AF6BA5-CC18-49AD-99A6-4833EB686B10>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://wikiba.se/ontology#Statement> .
<http://www.wikidata.org/entity/statement/Q33264821-71AF6BA5-CC18-49AD-99A6-4833EB686B10>	<http://www.wikidata.org/prop/statement/P1476>	"Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models"@en .
<http://www.wikidata.org/entity/statement/Q33264821-71AF6BA5-CC18-49AD-99A6-4833EB686B10>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://wikiba.se/ontology#BestRank> .